Capital One Financial Reaffirms Overweight Rating for Fennec Pharmaceuticals (TSE:FRX)

Fennec Pharmaceuticals (TSE:FRXGet Rating)‘s stock had its “overweight” rating reiterated by investment analysts at Capital One Financial in a note issued to investors on Wednesday, reports. Capital One Financial also issued estimates for Fennec Pharmaceuticals’ Q3 2022 earnings at ($0.24) EPS, Q4 2022 earnings at ($0.24) EPS, FY2022 earnings at ($0.92) EPS, Q1 2023 earnings at ($0.11) EPS, Q2 2023 earnings at ($0.12) EPS, Q3 2023 earnings at ($0.12) EPS, Q4 2023 earnings at ($0.13) EPS, FY2023 earnings at ($0.49) EPS, FY2024 earnings at $0.38 EPS, FY2025 earnings at $1.53 EPS and FY2026 earnings at $2.05 EPS.

Separately, Wedbush reiterated an “outperform” rating on shares of Fennec Pharmaceuticals in a research note on Thursday, May 12th.

Fennec Pharmaceuticals Stock Performance

Shares of FRX stock opened at C$9.89 on Wednesday. Fennec Pharmaceuticals has a one year low of C$4.95 and a one year high of C$13.25. The company’s 50-day moving average is C$8.73 and its 200 day moving average is C$7.75. The company has a market capitalization of C$257.80 million and a price-to-earnings ratio of -12.09. The company has a debt-to-equity ratio of 58.42, a quick ratio of 4.91 and a current ratio of 5.12.

Fennec Pharmaceuticals (TSE:FRXGet Rating) last posted its earnings results on Friday, August 12th. The biopharmaceutical company reported C($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of C($0.13) by C($0.11).

Fennec Pharmaceuticals Company Profile

(Get Rating)

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014.

See Also

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with's FREE daily email newsletter.